search
Back to results

Effect of a Pre Heparin Coated Dialysis Filter on Coagulation During Hemodialysis

Primary Purpose

Renal Failure

Status
Completed
Phase
Phase 4
Locations
Norway
Study Type
Interventional
Intervention
a pre-heparin-coated hemodialysis filter; Hepran
Sponsored by
Oslo University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Renal Failure focused on measuring Hemodialysis, Anticoagulation, Clotting, Coagulation, dalteparin, Clotting in the extracorporeal system during HD, Antithrombogenic property of Evodial HD filter, Anticoagulation during HD

Eligibility Criteria

18 Years - 90 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Stable HD patients of at least 18 years of age.
  • HD treatment for at least one month.
  • Dialysis time at least 4 hours three times per week.
  • Stable Hemoglobin value of at least 11 g/dl during the last 4 weeks.

Exclusion Criteria:

  • Use of warfarin and/or acetylsalicylic acid.
  • Disseminated malignant disease.
  • Clinical signs of infection.

Sites / Locations

  • Department of nephrology, Oslo University Hospital, Ullevål

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

No Intervention

Arm Label

Evodial

170 H

Arm Description

a pre-heparin-coated hemodialysis filter

Conventional filter

Outcomes

Primary Outcome Measures

Activation of the intravascular coagulation system during hemodialysis with use of a pre-heparin-coated filter compared to a conventional filter
Blood specimens for analysis of prothrombin fragment 1+2 and beta-thromboglobulin will be drawn at start of hemodialysis and after three and four hours of all hemodialysis sessions.

Secondary Outcome Measures

A secondary outcome measure is degree of clot score in the extracorporeal system during hemodialysis with use of a pre-heparin-coated filter compared to the conventional filter.
Degree of clot score will be evaluated in the venous drip chamber as follows: 1=normal (no signs of clot). 2=fibrinous ring, 3=clot and 4=stop in dialysis due to high degree of clotting

Full Information

First Posted
June 29, 2011
Last Updated
February 3, 2016
Sponsor
Oslo University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT01388270
Brief Title
Effect of a Pre Heparin Coated Dialysis Filter on Coagulation During Hemodialysis
Official Title
The Effect of a Heparin-coated Dialysis Filter (Evodial) on Clotting and Intravascular Coagulation During Hemodialysis (HD) When Compared to a Conventional Polyflux Filter (170H)
Study Type
Interventional

2. Study Status

Record Verification Date
February 2016
Overall Recruitment Status
Completed
Study Start Date
September 2011 (undefined)
Primary Completion Date
December 2015 (Actual)
Study Completion Date
January 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Oslo University Hospital

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to determine whether the heparin-coated dialysis filter is superior to a conventional filter during hemodialysis in twelve stable, chronic hemodialysis (HD) patients. The antithrombogenic properties of the heparin-coated dialysis filter and of the conventional filter will be compared by means of statistical tests.
Detailed Description
In the present study twelve chronic hemodialysis (HD) patients will be included. Exclusion criteria are use of acetylsalicylic acid and/warfarin, clinical signs of infection and disseminated malignant disease. For each patient four HD sessions will be investigated; alternating with use of the pre-heparin-coated filter or the conventional filter. Dalteparin is reduced to 50% of the conventional dose and is given as one single bolus dose at start of HD. The venous drip chamber will be visually inspected for evaluation of clot score during each HD session. The filter will be visually inspected for clot score at the end of each session. Blood specimens will be drawn systematically during each HD session to evaluate platelet and coagulation activity as well as anti Factor Xa activity, haematology and urea/creatinine to evaluate dialysis effect. The antithrombogenic properties of the pre-heparin-coated filter and the conventional filter will be compared by means of statistical tests. The hypothesis is that the pre-heparin-coated filter induces significantly less clot score in the extracorporeal system during hemodialysis and also significantly less intravascular activation of the coagulation system compared to the conventional filter.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Renal Failure
Keywords
Hemodialysis, Anticoagulation, Clotting, Coagulation, dalteparin, Clotting in the extracorporeal system during HD, Antithrombogenic property of Evodial HD filter, Anticoagulation during HD

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
12 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Evodial
Arm Type
Active Comparator
Arm Description
a pre-heparin-coated hemodialysis filter
Arm Title
170 H
Arm Type
No Intervention
Arm Description
Conventional filter
Intervention Type
Device
Intervention Name(s)
a pre-heparin-coated hemodialysis filter; Hepran
Other Intervention Name(s)
HeprAN membrane, polyacrylonitrile, heparin-grafted membrane
Intervention Description
Use of the pre-heparin-coated filter compared to the conventional filter in a cross over design
Primary Outcome Measure Information:
Title
Activation of the intravascular coagulation system during hemodialysis with use of a pre-heparin-coated filter compared to a conventional filter
Description
Blood specimens for analysis of prothrombin fragment 1+2 and beta-thromboglobulin will be drawn at start of hemodialysis and after three and four hours of all hemodialysis sessions.
Time Frame
Activation of the intravascular coagulation system is assessed during four dialysis sessions within a two weeks period for a single patient
Secondary Outcome Measure Information:
Title
A secondary outcome measure is degree of clot score in the extracorporeal system during hemodialysis with use of a pre-heparin-coated filter compared to the conventional filter.
Description
Degree of clot score will be evaluated in the venous drip chamber as follows: 1=normal (no signs of clot). 2=fibrinous ring, 3=clot and 4=stop in dialysis due to high degree of clotting
Time Frame
The degree of clot score in the extracorporeal system is assessed during four hemodialysis sessions that for a single patient take place within a time frame of two weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Stable HD patients of at least 18 years of age. HD treatment for at least one month. Dialysis time at least 4 hours three times per week. Stable Hemoglobin value of at least 11 g/dl during the last 4 weeks. Exclusion Criteria: Use of warfarin and/or acetylsalicylic acid. Disseminated malignant disease. Clinical signs of infection.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Solbjørg Sagedal, PhD
Organizational Affiliation
Oslo University hospital, Ullevål
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of nephrology, Oslo University Hospital, Ullevål
City
Oslo
ZIP/Postal Code
0407
Country
Norway

12. IPD Sharing Statement

Learn more about this trial

Effect of a Pre Heparin Coated Dialysis Filter on Coagulation During Hemodialysis

We'll reach out to this number within 24 hrs